Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Teaser: This review focuses on the latest developments in tau research for Alzheimer’s disease and other tauopathies, highlighting therapeutic approaches against antiphosphorylated tau using pharmacophore-based molecular and bioinformatics methods. Phosphorylated tau (P-tau) has received much attention in the field of Alzheimer’s disease (AD), as a potential therapeutic target owing to its involvement with synaptic damage and neuronal dysfunction. The continuous failure of amyloid β (Aβ)-targeted therapeutics highlights the urgency to consider alternative therapeutic strategies for AD. The present review describes the latest developments in tau biology and function. It also explains abnormal interactions between P-tau with Aβ and the mitochondrial fission protein Drp1, leading to excessive mitochondrial fragmentation and synaptic damage in AD neurons. This article also addresses 3D pharmacophore-based drug models designed to treat patients with AD and other tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Unfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Microtubule assembly, organization and dynamics in axons and dendrites
Conde, C., & Cáceres, A. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2631 · Cited by 1,086
Spreading of pathology in neurodegenerative diseases: a focus on human studies
Brettschneider, J., Tredici, K. D., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3887 · Cited by 790
Tau association with synaptic vesicles causes presynaptic dysfunction
Zhou, L., McInnes, J., Wierda, K., Holt, M., Herrmann, A. G., Jackson, R. J., Wang, Y.-C., Swerts, J., Beyens, J., Miskiewicz, K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15295 · Cited by 434 · cited 1×
“Tau is hyperphosphorylated at specific sites in AD neurons [42] by kinases and phosphatases.”
BackgroundSynaptic Impairment in Alzheimer’s Disease: A Dysregulated Symphony
Forner, S., Baglietto-Vargas, D., Martini, A. C., Trujillo-Estrada, L., & LaFerla, F. M. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.002 · Cited by 430
Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427
Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., Hogan, A.-M. L., Xie, S. X., Ballatore, C., Smith, A. B., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4922-11.2012 · Cited by 401
Dendritic Tau in Alzheimer’s Disease
Ittner, A., & Ittner, L. M. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.003 · Cited by 278
Structural Principles of Tau and the Paired Helical Filaments of Alzheimer's Disease
Mandelkow, E., Von Bergen, M., Biernat, J., & Mandelkow, E. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00053.x · Cited by 243
Biernat, J., & Mandelkow, E.-M. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.3.727 · Cited by 149
Miller, E. C., Teravskis, P. J., Dummer, B. W., Zhao, X., Huganir, R. L., & Liao, D. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12507 · Cited by 131 · cited 1×
“In AD, tau undergoes several aberrant changes that lead to neuronal damage including: (i) tau mislocalization; (ii) hyperphosphorylation [50,51]; and (iii) tau–Aβ interactions causing aggregation and/or fibrillation [52].”
BackgroundDeveloping therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122 · cited 1×
“P-taumediated therapeutic drug molecules can increase microtubule stability, inhibit P-tau production, as well as oligomerization and fibrillization, and activate phosphatase functions [69].”
BackgroundSynergistic interaction between amyloid and tau predicts the progression to dementia
Pascoal, T. A., Mathotaarachchi, S., Shin, M., Benedet, A. L., Mohades, S., Wang, S., Beaudry, T., Kang, M. S., Soucy, J., Labbe, A., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.005 · Cited by 101 · cited 1×
“Although amyloid β (Aβ) and phosphorylated tau (P-tau) are involved in disease progression [4], mounting evidence suggests that the role of P-tau in the progression and pathogenesis of AD is largely through the impairment of axonal transport of subcellular organelles, including mitochondria, lysosomes, vesicles and pr…”
BackgroundBrunden, K. R., Ballatore, C., Crowe, A., Smith, Lee, V. M.-Y., & Trojanowski, J. Q. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.031 · Cited by 93
Analysis of tauopathies with transgenic mice
Hutton, M., Lewis, J., Dickson, D., Yen, S.-H., & McGowan, E. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02123-2 · Cited by 91
Tau can switch microtubule network organizations: from random networks to dynamic and stable bundles
Prezel, E., Elie, A., Delaroche, J., Stoppin-Mellet, V., Bosc, C., Serre, L., Fourest-Lieuvin, A., Andrieux, A., Vantard, M., & Arnal, I. (2018) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0429 · Cited by 83
Espíndola, S. L., Damianich, A., Alvarez, R. J., Sartor, M., Belforte, J. E., Ferrario, J. E., Gallo, J.-M., & Avale, M. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.079 · Cited by 65
Puri, R., Suzuki, T., Yamakawa, K., & Ganesh, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.009688 · Cited by 60
The metamorphic nature of the Tau protein: dynamic flexibility comes at a cost
Sabbagh, J. J., & Dickey, C. A. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00003 · Cited by 31
Cited by
Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509
Self-citationDefective mitophagy in Alzheimer’s disease
Pradeepkiran, J. A., & Reddy, P. H. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101191 · Cited by 367
Self-citationZeng, X., Xiang, H., Yu, L., Wang, J., Li, K., Nussinov, R., & Cheng, F. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00557-6 · Cited by 308
Vijayan, M., Alvir, R. V., Alvir, R. V., Bunquin, L. E., Pradeepkiran, J. A., & Reddy, P. H. (2022) · Aging Cell · doi:10.1111/acel.13663 · Cited by 40
Self-citation
Metadata
- Authors
- Pradeepkiran, J. A., Reddy, A. P., & Reddy, P. H.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 24
- Issue
- 2
- Pages
- 616-623
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2900998599
- Cited by
- 52
- References
- 22
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.